Clinical Research of Individualized Therapy in Advanced Non-Small Cell Lung Cancer Guiding by & Nbsp;detection of ERCC1 Protein

GAO Zhi-qiang,HAN Bao-hui,SHEN Ce,JIN Xian-qiao,DONG Jing-cheng,WAN Huan-ying,TANG Jie,SHEN Jie,GU Ai-qin,JIANG Li-yan

DOI: https://doi.org/10.3969/j.issn.1007-3969.2013.05.002

2013-01-01

Abstract:10.3969/j.issn.1007-3969.2013.05.002

What problem does this paper attempt to address?

Randomized and controlled clinical research of personalized therapy for advanced non-small cell lung cancer according to ERCC1 and RRM1

CHEN Jia,HE Song,ZHANG Xiao-dong,GUO Yan,ZHU Ya-fang,JI Zhi-gu,LU Jun-guo,TAO Yu,ZHU Xing-hua,WANG Jian-hong,YANG Shu-yun,TAN Qing-he

DOI: https://doi.org/10.3969/j.issn.1672-2353.2012.09.008

2012-01-01

Abstract:Objective To select sensitive drugs according to the detection results of excision repair cross-complementation group 1(ERCC1) and ribonucleotide reductase M1(RRM1) in advanced non-small cancer lung cancer(NSCLC) patients and observe the effect differences so as to guide individual treatment.Methods Combined detection of ERCC1 and RRM1 of tumor cells was performed in advanced NSCLC patients diagnosed pathologically.The patients were divided into two groups with a proportion of 2:1.The control group received gemcitabine and cisplatin,while the gene group was divided into four subgroups according to ERCC1 and RRM1 and received individual therapy separately.The short-term and long-term effects were observed.Results A total of 174 patients were observed,and the overall efficacy rate was 44.2%.The efficacy rate was 37.5% in the control group and 47.5% in the gene group.The difference was statistically insignificant.The efficacy rate of ERCC1(-)(56.7%) was higher than that of ERCC1(+)(37.9%)in gene group,and the difference was statistically significant.The median progression-free survival,median survival and 1 year survival rate in each group had no significant difference.Conclusion The use of individual therapy in patients with lower expressions of ERCC1 can obtain higher efficacy rate,while the patients with higher expressions of ERCC1 may have drug resistance to platinums.
Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Chenyi Ren,He Cao,Jing Zheng,Wenjia Sun,Jianya Zhou

DOI: https://doi.org/10.3779/j.issn.1009-3419.2023.102.14

2023-01-01

Abstract:Lung cancer is the most common malignancy in the world and the leading cause of cancer death. Human epidermal growth factor receptor 2 (HER2) positive non-small cell lung cancer (NSCLC) refers to the NSCLC caused by mutation, amplification or overexpression of the HER2 gene, resulting in its dysfunction. HER2 is the most active receptor in the HER family and can combine with other members to form dimers, which can activate multiple signaling pathways and regulate cell proliferation, differentiation, migration and apoptosis. In NSCLC, HER2 positivity is usually considered a poor prognostic marker. At present, the diagnosis and treatment of HER2-positive NSCLC are not mature. Immunohistochemistry (IHC), next generation sequencing (NGS) and other technologies are often used to detect the positive status of HER2 mutation, amplification or overexpression. In previous studies, antitumor drugs did not show ideal therapeutic effects in HER2-positive NSCLC. However, in recent years, related researches have shown that antibody-drug conjugates (ADCs) and new tyrosine kinase inhibitors (TKIs) in targeted therapy show good antitumor activity against HER2 positive NSCLC. This article summarized the progress in diagnosis and treatment of HER2-positive NSCLC, so as to provide reference for subsequent researches. .
Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

TAN Fen-lai,WANG Yin-xiang,YUAN Xiao-fen,DING Lie-ming,HU Bei,ZHANG Li,ZHOU Jian-ying,SHENG-TU Jian-zhong,SUN Yan

2011-01-01

Abstract:Non-small cell lung cancer(NSCLC) is the leading cause of cancer mortality worldwide.The management of NSCLC has changed dramatically in the last decade.A number of well documented clinical studies demonstrated that the epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) showed a better survival benefit comparing to the standard treatments in patients with advanced/metastatic NSCLC.EGFR-TKIs,including gefitinib and erlotinib,have been used in first-line,second-line and more other settings with obvious survival benefits in a subgroup of patients with EGFR mutations.Moreover,icotinib,a novel EGFR-TKIs developed by BetaPharma Inc.,has finished its phase III trial(ICOGEN) with encouraging efficacy and safety profile in China recently.This review will summarize the results of clinical trials of erlotinib,gefitinib or icotinib for patients with advanced NSCLC.
Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

T. B. Wang,N. L. Zhang,S. H. Wang,H. Y. Li,S. W. Chen,Y. G. Zheng

DOI: https://doi.org/10.4238/2014.may.9.15

2014-01-01

Genetics and Molecular Research

Abstract:We examined mRNA expression levels of ERCC1, BRCA1, RRM1, and human beta-tubulin-III (TUBB3) in non-small-cell lung carcinoma (NSCLC) patients and investigated the association between expression of these genes and the clinical outcome of NSCLC treatment. A total of 366 patients who underwent surgery for NSCLC were included in this study. All patients received third-generation platinum-based chemotherapy as first-line treatment. The relative cDNA quantification for ERCC1, RRM1, BRCA1, and TUBB3 was determined using a fluorescence-based, real-time detection method. We found that low expression of ERCC1 and BRCA1 was associated with a good response to platinum-based chemotherapy, with an odds ratio [95% confidence interval (CI)] of 2.09 (1.33-3.27) and 2.92 (1.85-4.62), respectively. Multivariate Cox regression analysis indicated that patients with low expression of ERCC1 and BRCA1 attained a longer overall survival time than those with high expression, with a hazard ratio (95% CI) of 0.42 (0.23-0.77) and 0.39 (0.21-0.71), respectively. However, RMM1 and TUBB2 expressions were not correlated with clinical outcome of NSCLC. In conclusion, we found that low expression of ERCC1 and BRCA1 can be useful for selecting NSCLC patients who would benefit from chemotherapy and warrants further investigation in prospective studies.
A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Feng Jiang,Heng Zhao,Xiaofei Li,Lunxu Liu,Yang Liu,Jian Hu,Xiangning Fu,Yin Li,Yijun Xu,Deruo Liu,Haiying Yang,Lin Xu

DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.e20523

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e20523 Background: Clinical characteristics of lymph metastases are hetergeneous in the patients with T1 non-small cell lung cancer (NSCLC). Preoperative assessment of lymph metastases is essential to determine the appropriate treatment regimens. The study was designed to evaluate those potential factors that may influence lymph metastases. Methods: We conduct the study based on a national collaborative prospective lung cancer database (designed by LinkDoc Technology Co, Ltd.). The patients with pathologically diagnosed T1 non-small cell lung cancer who received surgical resection from 2014 to 2017 were enrolled. The univariate and multivariate logistic regression analyses were performed to analyze the risk factors that influnce lymph metastases. Results: A total of 10885 subjects were recruited in the study including 1808 patients with lymph metastases (16.6%) (N1: 640 patients/5.9%; N2: 1159 patients/10.6%). Of all the pN2 patients, 754(65.1%) patients were observed with N1 lymph nodes and 405 (34.9%) patients with skip metastases. The univariate and multivariate analyses showed the CEA levels before surgeries, tumor size, degree of differentiation, and tubular cancer embolus were potential risk factors of lymph metastases in the total population and in N2 population. The tuerculosis comorbidity was also found to be significantly related to lymph metastases. In the pN2 population, age and smoking history were predictive for N2 skip metastases. Conclusions: The relevance between clinical and tumor biological characteristics of the NSCLC patients, and lymph metastases were demonstrated in the Chinese real-world study that will offer clinical complementary guidance on management of T1 NSCLC patients in practice. Clinical trial information: NCT03413956.
Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

Jingyao Li,Yang Qiu,Junxiu Yi,Xi Liu,Shixin Zhang,Deli Tan,Tao Jing,Yi Liao,Meng Tang,Jie Liu,Haidong Wang

DOI: https://doi.org/10.1155/2021/8820691

IF: 4.501

2021-09-23

Journal of Oncology

Abstract:Objective. To investigate the clinical significance of the mRNA expression of RRM1, TUBB3, and ERCC1 in non-small-cell lung cancer (NSCLC) tissues for the selection of adjuvant/postoperative chemotherapy regimens. Methods. Patients diagnosed with stage Ib-IIIa NSCLC were enrolled and randomly divided into a control group (undetected group) and an experimental group (detected group) after radical operation. The control group randomly received chemotherapy with gemcitabine plus cisplatin or paclitaxel plus cisplatin. The mRNA expression of RRM1, TUBB3, and ERCC1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen. The disease-free survival (DFS) of the control group and experimental group was compared. Results. Pathological type, stage, gene expression detection, and treatment method were not significantly correlated with DFS ( P > 0.05 ). In the subgroups treated with gemcitabine, the median DFS was 17 months in the detected group and 10.5 months in the undetected group (hazard ratio = 0.2147, 95% confidence interval: 0.07909–0.5827, P = 0.0025 ). Multivariate regression analysis was performed to analyse whether gene expression detection was independently correlated with DFS in the subgroups treated with gemcitabine ( P = 0.025 ). In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment ( P = 0.0039 ). Conclusions. The selection of chemotherapy regimen based on mRNA expression of the RRM1, TUBB3, and ERCC1 genes may improve selection of candidate patients to receive clinical chemotherapy. However, large-scale prospective clinical studies are needed for in-depth investigation.

oncology
First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Ying Li,Lin Run Wang,Jian Chen,Yan Lou,Guo Bing Zhang

DOI: https://doi.org/10.1155/2014/960458

2014-01-01

Disease Markers

Abstract:AIM:To evaluate the predictive value of RRM1, ERCCl, and BRCA1 expression in Chinese NSCLC patients treated with gemcitabine and cisplatin.METHODS:Real-time fluorescent quantitative PCR was used to determine the RRM1, ERCC1, and BRCA1 mRNA expression levels of peripheral blood in late-stage NSCLC patients. The relationship between peripheral blood and mRNA expression in tumor tissues was analyzed further.RESULTS:In terms of the tumor susceptibility to chemotherapy, the response rate in the low-RRM1-expression group was significantly greater than in the high-expression group (52.9% versus 5.9%, χ(2) test, P = 0.007). Subjects with low peripheral blood RRM1 expression survived longer than those with high RRM1 expression (15.5 versus 12.0 months, logrank 3.980, P = 0.046). Linear correlations were observed between peripheral blood and tumor tissue expression levels for RRM1 (R (2) = 0.045, P = 0.048) and BRCA1 (R(2) = 0.021, P = 0.001).CONCLUSION:Our study demonstrates increased survival and superior efficacy of gemcitabine and cisplatin combination chemotherapy in the treatment of NSCLC patients with low peripheral blood RRM1 expression. The linear correlations of the relative expression of mRNA were observed between peripheral blood and tumor tissue expression levels for RRM1 and BRCA1. RRM1 gene expression may contribute to chemotherapy sensitivity and may be an indicator of survival. It was significant to individual chemotherapy of patients with advanced NSCLC who do not have sufficient tumor tissue.
Analysis of A Case of Advanced Non-small Cell Lung Cancer Treated with Individualized Therapy

WANG Liuchun,LIU Zhujun,XIAO Jianyu,YUAN Jing,LI Kai

DOI: https://doi.org/10.3969/j.issn.1000-8179.2009.15.015

2009-01-01

Chinese Journal of Clinical Oncology

Abstract:The prognosis of patients with non-small cell lung cancer is poor and the overall survival is 5-6 months and the one-year survival rate is 20%～25%. Regular chemotherapy can prolong patient survival for 2～3 months. Currently, new treatments such as antiangiogenic and target therapy have appeared. At the same time individualized therapy according to the performance of patients, pathological type and biological characteristics of tumor cell is considered in order to reach good therapeutic effect and survival. We will introduce one patient with non-small cell lung cancer treated with individualized therapy in our department. Chemotherapy and anti-vascular therapy achieved good results in this patient. CT perfusion and cECs were applied to evaluate the effect of the therapy.
Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer

Rafael Rosell,Christian Manegold,Teresa Moran,Pilar Garrido,Remei Blanco,Pilar Lianes,Rolf Stahel,Jose Manuel Trigo,Jia Wei,Miquel Taron

DOI: https://doi.org/10.3816/clc.2008.s.012

IF: 4.84

2008-01-01

Clinical Lung Cancer

Abstract:Metastatic non-small-cell lung cancer remains a fatal disease with a median survival of < 1 year. A critical challenge is to develop predictive markers for customizing platinum-based treatment. The first studies focused on the excision repair cross-complementing 1 (ERCC1) gene in this difficult task. Several layers of evidence indicate that ERCC1 mRNA expression could be a predictive marker for cisplatin alone or in combination with certain drugs such as etoposide, gemcitabine, and 5-fluorouracil but not in combination with antimicrotubule drugs. Several retrospective studies demonstrated an impressive survival advantage for gemcitabine plus cisplatin but not for other combinations in tumors with low ERCC1 expression. A customized phase III ERCC1-based trial met the primary endpoint of improvement in response but not in survival, leading us to hypothesize that docetaxel might not be the most appropriate partner for cisplatin in the presence of low ERCC1 levels or for gemcitabine in the presence of high ERCC1 levels. A phase II study demonstrated the feasibility of combining carboplatin, gemcitabine, docetaxel, and vinorelbine according to ERCC1 and ribonucleotide reductase subunit M1 expression levels. These findings highlight the importance of continual learning, and decision-making strategies for customizing treatment should reflect the limitations of our knowledge.
Long-term Survival with Targeted Therapy in an Advanced Non-Small Cell Lung Cancer Patient Based on Genetic Profiling.

Fang-Fang Shen,Wei Guo,Rui-Fen Tian,Yi Guo,Yan-Li Yang,Xia Song

DOI: https://doi.org/10.21037/tlcr.2020.01.21

2020-01-01

Translational Lung Cancer Research

Abstract:Non-small cell lung cancer (NSCLC) is a profoundly devastating disease that is the leading cause of cancer-related death worldwide. With the rapid development of next-generation sequencing (NGS), which has supplied the ability to decode tumors at the DNA level, so that targeted therapy plays a crucial role in improving NSCLC survival. We first reported a 32-year-old Chinese female patient received the ninth-line treatment, who was initially diagnosed with advanced NSCLC with EGFR 19 deletion. The patient had a satisfactory clinical response to initial gefitinib treatment. Subsequently, an EGFR T790M mutation was detected from plasma-derived circulating tumor DNA (ctDNA) by ddPCR after disease progression, while NGS did not. Osimertinib was still tried but had no therapeutic effect. Then the disease even progressed on the administration of chemotherapy and gefitinib in succession. Rebiopsy for NGS detection was performed, and gefitinib plus anlotinib/vemurafenib were tried. And then, gefitinib plus crizotinib were administrated for MET amplification after the third biopsy. Furthermore, chemotherapy combined with immunotherapy was performed due to the PD-L1 positive expression. Up to now, osimertinib treatment was undertaken to base on an EGFR exon 20 T790M mutation using NGS-based genotyping in cerebrospinal fluid (CSF) ctDNA. Tumor genome dynamic monitoring can identify tumor driving genes and drug resistance mechanisms to guide tumor treatment. This study found that the total survival time of advanced NSCLC patients was more than four years after chemoradiotherapy and targeted therapy, indicating the significance of dynamic monitoring of gene alterations for cancer treatment.
Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Xiao-ping Qian,Bao-rui Liu,Mei-qi Shi,Xin-zi Liu,Wen-jing Hu,Zheng-yun Zou,Jia Wei

DOI: https://doi.org/10.3760/cma.j.issn.0253-3766.2009.01.008

2009-01-01

Abstract:OBJECTIVE:To investigate the correlation of the mRNA expression level of excision repair cross-complementing group 1 (ERCC1) gene with clinicopathological parameters and clinical outcome in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy.METHODS:The mRNA expression of ERCC1 in formalin-fixed paraffin-embedded primary tumor specimens was measured by real-time quantitative reverse transcriptase polymerase chain reaction. The association between ERCC1 expression levels and clinicopathological parameters in NSCLC patients was analyzed.RESULTS:The median value of ERCC1 mRNA expression level compared with beta-actin in tumor specimens of 61 NSCLC patients was 0.48. There was no correlation between ERCC1 expression and clinicopathological parameters. Patients with low expression of ERCC1 mRNA (less than 0.35, 0.28, respectively) had a significantly longer median time to progression (TTP) (14.3 vs. 8.0 months, P = 0.028) and overall survival (OS) (28.4 vs. 12.9 months, P = 0.0064) than those with high expression. Multivariate analysis showed that a low ERCC1 mRNA expression was an independent factor for OS.CONCLUSION:Our findings suggest that intratumoral ERCC1 mRNA expression level, although is uncorrelated with clinicopathological parameters, is an independent predictive marker for survival of the patients with NSCLC receiving platinum-based chemotherapy, and may provide critical information for personalized chemotherapy.
Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Xinghao Ai,Jiuwei Cui,Jiexia Zhang,Rongrong Chen,Wen Lin,Congying Xie,Anwen Liu,Junping Zhang,Weihua Yang,Xiaohua Hu,Xiaohua Hu,Qiong Zhao,Chuangzhou Rao,Yuan-Sheng Zang,Ruiling Ning,Pansong Li,Lianpeng Chang,Xin Yi,Shun Lu

DOI: https://doi.org/10.1158/1078-0432.ccr-20-3063

IF: 13.801

2020-11-13

Clinical Cancer Research

Abstract:PURPOSE: Clonal architecture is fundamental for the understanding of cancer biology and therapy; however, multiregional sampling in advanced-stage cancers is not always applicable. This prospective clinical trial was to investigate whether paired tissue and circulating tumor DNA (ctDNA) could describe the clonal architecture of advanced non-small cell lung cancer (NSCLC) and its association with clinical outcome (NCT03059641).PATIENTS AND METHODS: Paired tumor and plasma ctDNA samples were sequenced by target-capture deep sequencing of 1,021 genes. Clonal dominance analysis was performed on the basis of PyClone.RESULTS: Overall, 300 treatment-naïve patients with stage IIIB-IV NSCLC were recruited from 14 centers. Of the 94 patients with available ctDNA data for EGFR clonal architecture analysis, 72 (76.6%) showed EGFR as the dominant clone. The median progression-free survival was longer for these patients than for the 22 patients whose EGFR was nondominant clone [11 vs. 10 months; HR, 0.46; 95% confidence interval (CI), 0.24-0.88; P = 0.02]. The difference was more significant if both tissue and ctDNA defined EGFR as dominant clone (n = 43) versus those not (n = 8; 11 vs. 6 months; HR, 0.13; 95% CI, 0.04-0.50; P = 0.003). Moreover, multivariate Cox proportional HR analysis demonstrated EGFR clonal architecture as an independent prognostic indicator of the efficacy of EGFR-tyrosine kinase inhibitors (TKIs).CONCLUSIONS: Paired tissue and ctDNA could be analyzed for clonal architecture in advanced cancer. EGFR mutations do not always make up a dominant clone in advanced NSCLC, which was associated with the efficacy of EGFR-TKIs in NSCLC.

oncology
Relation between the expression of ERCC1 and the clinicopathology characteristics in advanced non-small cell lung cancer

Xie Weimin,Liao Xiaoli,Yao Kaitao,Wang Hongxue,Fang Liang,Lin Yan,Chen Jun,Chen Falong,Li Yongqiang,LU Yongkui,Hu Xiaohua

2008-01-01

Abstract:Objective To investigated the association between the expression of DNA repair gene ERCC1 with the clinicopathology characteristics in patients with advanced noninitial chemotherapy treatment non-small cell lung cancer ( NSCLC ). Methods The ERCC1 expression in 64 NSCLC patients was examined with the method of immunohistochemistry, expression differences of ERCC1 and its relationship with the patients clinicopath- ology characteristics were analyzed. Results There were 28 cases expressing ERCC1 (43. 8%). Expression rates of ERCC1 in smokers was 27. 8% and was significantly lower than that in non-smokers (64.3%). The expression of ERCC1 in lung adenocarcinomas were lightly higher than squa- mous cell carcinomas,but the differenc was not significant. There were no significant differences between the expression of ERCC1 and the different TNM stages,gender,ages and pathological classification. Conclusion In non-small cell lung cancer,expression of ERCC1 was significantly higher in smokers than in non-smokers.
Dilemma and prospect of personalized therapy in non-small cell lung cancer

WANG Zhi-jie,WANG Jie

DOI: https://doi.org/10.3760/cma.j.issn.1006-9801.2010.01.006

2010-01-01

Abstract:Personalized therapy has became a main method to break through efficacy of chemotherapy in lung cancer. At present, we have got a few progressions in personalized therapy, but which are very limited. This review discourses upon the dilemma and hope of individualized treatment from the following ways:limitation of based on histology type to determine treatment regimens, undecided sequential therapy after failure of TKI as front-line therapy for advanced NSCLC patients with EGFR mutation, clinical study of maintenance therapy and EGFR mutation detection based on peripheral blood being trap or surrogate for tumor tissue to direct personalized TKI therapy.
Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

Cunte Chen,Siyang Maggie Liu,Yedan Chen,Qiuxiang Ou,Hua Bao,Ling Xu,Yikai Zhang,Jia-Tao Zhang,Wenzhao Zhong,Qing Zhou,Xue-Ning Yang,Yang Shao,Yi-Long Wu,Si-Yang Liu,Yangqiu Li

DOI: https://doi.org/10.1007/s00262-022-03330-1

2023-04-19

Abstract:Tumor response T cells, which have specific T cell receptor (TCR) rearrangements in tumor-infiltrating lymphocytes, determine their ability to interact with the mutation-derived neoantigens presented by antigen-presenting cells. Little is known about the genetic alterations related to specific TCR clones in non-small cell lung cancer (NSCLC) patients who have an epidermal growth factor receptor ( EGFR ) mutation. In this study, tumor tissues were collected from 101 patients with stage II/III resectable NSCLC with an EGFR mutation (57 patients were treated with gefitinib and 44 were treated with chemotherapy) in the ADJUVANT-CTONG1104 trial for high-throughput TCRβ V region and exome sequencing. Ten clonal TCRs were associated with EGFR exon 19 deletion (del), EGFR exon 21 mutation (L858R), RB1 alteration, TP53 exon 4/5 missense mutation, TP53 nonsense mutation, or copy number gains in NKX2-1 and CDK4 . Among the TCRs, there was frequent use of Vβ20-1Jβ2-3 specifically for EGFR exon 19 del or Vβ9Jβ2-1 specifically for EGFR exon 21 mutation (L858R), and these were significantly associated with favorable overall survival (OS) for NSCLC patients harboring EGFR exon 19 del or exon 21 L858R, particularly in the adjuvant gefitinib setting. Moreover, in comparison with the chemotherapy-preferable (CP) group, higher frequencies of Vβ20-1Jβ2-3 and Vβ9Jβ2-1 were found in the highly TKI-preferable (HTP) or TKI-preferable (TP) groups. Altogether, we identified ten TCR rearrangements specific for genetic alterations in NSCLC. Importantly, high abundance Vβ20-1Jβ2-3 or Vβ9Jβ2-1 may be an immune biomarker for guiding adjuvant gefitinib decisions for NSCLC patients harboring EGFR exon 19 del or EGFR exon 21 L858R.

oncology,immunology
Expression Of Ercc1 And Class Iii Beta-Tubulin In Resected Non-Small Cell Lung Cancer And Its Correlation With Platinum-Based Adjuvant Chemotherapy

Shucai Zhang,Qi Li,Quan Zhang,Jinghui Wang,Haiqing Zhang,Zongde Zhang,Qunhui Wang,Xinjie Yang,Yanfei Gu,Hui Zhang

DOI: https://doi.org/10.1177/172460081002500304

2010-01-01

Abstract:Objective: To explore the relationship between the expression of excision repair cross-complementation group 1 (ERCC1) and class III beta-tubulin and the clinical characteristics and overall survival of patients with non-small cell lung cancer (NSCLC).Methods: Immunohistochemical analysis was used to determine the protein expression of ERCC1 and class III beta-tubulin in 160 completely resected NSCLC primary tumor samples, 50 of which were paired with adjacent normal tissue samples and another 40 benign lung lesion tissue samples as controls. Clinical data at baseline, disease-free survival and overall survival were also collected. Univariate and multivariate Cox models were used to analyze the risk factors.Results: In 160 tumor samples, the ERCC1 and class III beta-tubulin positive rates obtained with immunohistochemistry were 46.9% and 49.4%, respectively. Both biomarkers had a higher positive rate in male patients. For patients who did not receive adjuvant chemotherapy, ERCC1 positivity was associated with longer survival (median survival time 73 vs 53 months, p=0.041), while in patients treated with platinum chemotherapy, ERCC1 positivity tended to be associated with poor survival (median survival time 41 vs 54 months, p=0.014). Class III beta-tubulin positivity was also associated with poor survival (median survival time 38 vs 58 months, p<0.001), but had no influence on the survival of patients who did not receive adjuvant chemotherapy.Conclusions: ERCC1 and class III beta-tubulin could be important survival predictors for completely resected NSCLC patients treated with adjuvant chemotherapy. Further prospective studies need to be performed to test this hypothesis in Chinese patients.
Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

SONG Xiang-qun,NING Rui-ling,LUO Yuan,CHEN Jun,YU Qi-tao,ZENG Ai-ping,LI Zhi-ge

DOI: https://doi.org/10.3969/j.issn.1673-5269.2006.22.009

2006-01-01

Abstract:OBJECTIVE:To determine the predictive value of excision repair cross complement-1 (ERCC-1) expression and the sensitivity of cisplatin-based chemotherapy in advance non-small cell lung cancer (NSCLC). METHODS: From February 1,2000 to June 30,2004, 51 specimens of paraffin-embedded tissues of pathologically confirmed advanced NSCLC were studied. All patients received cisplatin contained regimen chemotherapy. The expression of ERCC-1 in tumor samples was examined by the immunohistochemical supervisiontm method. The response rates and survival data were analyzed according to the over-expression or not of the parameter. RESULTS: In these 51 patients, over expression rates of ERCC-1 was 64.7%(33/51). The response rate of cisplatin-based chemotherapy in negative group and over expression group of ERCC-1 were 72.2% and 42.4% respectively,being a significant difference (χ2=4.151, P=0.042). The average survival time in negative group and over-expression group were 12.5 and 9.3 months for ERCC-1, being a significant difference ( χ2= 5.61, P=0.018). The 1-year survival time in negative group and over-expression group were 72.2% and 30.3% for ERCC-1, being a significant diference (χ2=8.267, P=0.004). CONCLUSION: ERCC-1 can be used as a molecular marker of cisplatin sensitivity and prognosis in advanced NSCLC patients.
Single Nucleotide Polymorphism in ERCC1 118C→T Predicts the Outcome of NSCLC Patients Receiving Platinum-Based Chemotherapy

QIAN Xiaoping,LIU Baorui,YAN Wenyue,WANG Lifeng,WEI Jia,XIE Li,HU Jing,LIU Xinzi,YU Lixia

DOI: https://doi.org/10.3969/j.issn.1672-4992.2011.10.28

2011-01-01

Journal of Modern Oncology

Abstract:Objective:ERCC1 is emerging as essential elements in repairing platimun-DNA adducts.The aim of this study is to investigate whether the single nucleotide polymorphism(SNP) in Excision repair cross-complementation group 1(ERCC1) 118C→T is associated with the clinical prognosis of platinum-based chemotherapy in non-small-cell lung cancer.Methods: SNP of ERCC1 118C→T was genotyped by PCR-restrictive fragment length polymorphism(PCR-RFLP).The pathological parameters and survival data were evaluated according to the different genotypes in 47 NSCLC patients.Results: ERCC1 118C→T was not related to clinic pathological parameters in NSCLC(P0.05).The median survival of patients with C/C genotypes was 25.0 months compared to 10.5 months of C/T or T/T genotypes(P=0.012).In Cox regresssion models,ERCC1 118C→T was significantly associated with overall survival time of NSCLC patients(P=0.015).Conclusion: ERCC1 codon118 SNP might be a predictive marker of survival for NSCLC patients receiving platinum-based chemotherapy.
Clinical Progress for the EGFR-TKI Combined with Radiotherapy in Non-Small Cell Lung Cancer

Lin Juan,Han Shuiyun,Xu Yaping

DOI: https://doi.org/10.3760/cma.j.issn.1008-1372.2016.06.004

2016-01-01

Abstract:At present,the treatment for non-small cell lung cancer (NSCLC) consists of surgery,radiation,chemotherapy,targeted therapy,etc.The epidermal growth factor receptor (EGFR) gene mutation opened a new era of individualized treatment.Multidisciplinary treatment come next after the combination of different treatment approaches,and the modality of targeted therapy like epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in combination with radiation was included.The present work reviews clinical progress for the EGFR-TKI combined with radiotherapy in advanced NSCLC.
Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer

Yufan Yang,Jianyang Wang,Jingbo Wang,Xiaotian Zhao,Tao Zhang,Yin Yang,Jiaohui Pang,Qiuxiang Ou,Linfang Wu,Xin Xu,Kunpeng Xu,Jingjing Zhao,Na Bai,Peng Yang,Sha Wang,Luhua Wang,Nan Bi

DOI: https://doi.org/10.1016/j.canlet.2023.216569

IF: 9.756

2023-12-15

Cancer Letters

Abstract:Progression occurs in approximately two-thirds of patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving chemoradiation and consolidation immunotherapy. Molecular indicators for predicting treatment outcomes are under development. A novel metric, the ratio of mean to max variant allele frequency (mmVAF), was derived from 431 pre-treatment tissue biopsies from The Cancer Genome Atlas and evaluated in serial circulating tumor DNA (ctDNA) from 70 LA-NSCLC patients receiving definitive radiotherapy/chemoradiotherapy (RT/CRT) with/without immunotherapy. High mmVAFs in pre-treatment tissue biopsies, indicating clonal predominant tumors ( P < 0.01), were associated with inferior overall survival [OS, hazard ratio (HR): 1.48, 95 % confidence interval (CI): 1.11–1.98]. Similar associations of mmVAF with clonality ( P < 0.01) and OS (HR: 2.24, 95 % CI: 0.71–7.08) were observed in pre-treatment ctDNA. At 1-month post-RT, ctDNA mmVAF-high patients receiving consolidation immunotherapy exhibited improved progression-free survival (PFS) compared to those who did not (HR: 0.14, 95 % CI: 0.03–0.67). From the baseline to week 4 of RT and/or 1-month post-RT, survival benefits from consolidation immunotherapy were exclusively observed in ctDNA mmVAF-increased patients (PFS, HR: 0.39, 95 % CI: 0.14–1.15), especially in terms of distant metastasis (HR: 0.11, 95 % CI: 0.01–0.95). In summary, our longitudinal data demonstrated the applicability of ctDNA-defined clonality for prognostic stratification and immunotherapy benefit prediction in LA-NSCLC.

oncology

Clinical Research of Individualized Therapy in Advanced Non-Small Cell Lung Cancer Guiding by & Nbsp;detection of ERCC1 Protein

Randomized and controlled clinical research of personalized therapy for advanced non-small cell lung cancer according to ERCC1 and RRM1

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Analysis of A Case of Advanced Non-small Cell Lung Cancer Treated with Individualized Therapy

Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer

Long-term Survival with Targeted Therapy in an Advanced Non-Small Cell Lung Cancer Patient Based on Genetic Profiling.

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Relation between the expression of ERCC1 and the clinicopathology characteristics in advanced non-small cell lung cancer

Dilemma and prospect of personalized therapy in non-small cell lung cancer

Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

Expression Of Ercc1 And Class Iii Beta-Tubulin In Resected Non-Small Cell Lung Cancer And Its Correlation With Platinum-Based Adjuvant Chemotherapy

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

Single Nucleotide Polymorphism in ERCC1 118C→T Predicts the Outcome of NSCLC Patients Receiving Platinum-Based Chemotherapy

Clinical Progress for the EGFR-TKI Combined with Radiotherapy in Non-Small Cell Lung Cancer

Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer